Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progestogen-only contraception

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    496 result(s) found for: Progestogen-only contraception. Displaying page 7 of 25.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2004-001173-26 Sponsor Protocol Number: 580299/012,107476 - 477 - 479 - 481 Start Date*: 2004-10-08
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Long-term follow-up: A long-term, open, follow-up of the immunogenicity and safety of the vaccine in healthy female subjects vaccinated either pre- or post-menarche in the HPV-012 study. Primary: A...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent persistent HPV-16 and HPV-18 infection and HPV-16 and HPV-18 associated cervical neoplasia.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-002283-27 Sponsor Protocol Number: 1812VA323 Start Date*: 2020-03-18
    Sponsor Name:Shionogi B.V.
    Full Title: A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study of S-600918 in patients with refractory chronic cough
    Medical condition: Refractory chronic cough
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004278-23 Sponsor Protocol Number: CT-P42_3.1 Start Date*: 2021-03-16
    Sponsor Name:CELLTRION Inc.
    Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-001947-30 Sponsor Protocol Number: PB-102-F51(CLI-00657AA1-03) Start Date*: 2019-04-29
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000066-29 Sponsor Protocol Number: RD.03.SPR.114384 Start Date*: 2017-05-15
    Sponsor Name:Galderma R&D
    Full Title: Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp
    Medical condition: Thin or non-hyperkeratotic and non-pigmented Actinic Keratosis on the face and scalp
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10020648 Hyperkeratoses HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003118-15 Sponsor Protocol Number: 97807 Start Date*: 2017-10-31
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: A double blind, placebo controlled, randomised dose escalation trial to investigate the safety and efficacy of topical salbutamol in the improvement of scar appearance when applied to approximated ...
    Medical condition: Improvement of (hypertrophic)scar appearance
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020879 Hypertrophic scar PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003060-40 Sponsor Protocol Number: TICSI Start Date*: 2017-01-17
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition
    Medical condition: Adverse effects of prescribed glucocorticoid therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10068501 Cushing's syndrome, steroid-induced LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004973-42 Sponsor Protocol Number: 1289.32 Start Date*: 2017-11-21
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early inter...
    Medical condition: attenuated psychosis syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-000346-61 Sponsor Protocol Number: DTG-01-01 Start Date*: 2017-02-20
    Sponsor Name:Blueclinical, Ltd.
    Full Title: A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects
    Medical condition: Human immunodeficiency virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020194 HIV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004163-12 Sponsor Protocol Number: RP2017-001 Start Date*: 2018-01-28
    Sponsor Name:ReposPharma
    Full Title: A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin
    Medical condition: Squamous cell cancer or adenocarcinoma, including primary cancer of the liver, of the gastrointestinal tract or cancer of unknown origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10017985 Gastrointestinal neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003178-25 Sponsor Protocol Number: SNSP113-19-201 Start Date*: 2019-11-19
    Sponsor Name: Synspira Therapeutics, Inc.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Effect of Inhaled SNSP113 in Adult Subjects with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001938-11 Sponsor Protocol Number: C22-109-08 Start Date*: 2022-08-18
    Sponsor Name:Pharma Holdings AS
    Full Title: A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus
    Medical condition: Eradication of Staphylococcus aureus from the nose.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10067910 Staphylococcal colonization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003023-14 Sponsor Protocol Number: CSUC-02/21 Start Date*: 2021-09-02
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: Pharmacokinetics of Cobitolimod Enemas in Participants with active Ulcerative Colitis
    Medical condition: Moderate to Severe Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006053-22 Sponsor Protocol Number: NLX-112-DYS-101 Start Date*: 2021-09-22
    Sponsor Name:Neurolixis SAS
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease
    Medical condition: Parkinson´s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006106-23 Sponsor Protocol Number: 2020/3210 Start Date*: 2021-07-21
    Sponsor Name:Gustave Roussy
    Full Title: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients
    Medical condition: Untreated operable small triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003447-25 Sponsor Protocol Number: CHUBX2021/08 Start Date*: 2021-12-01
    Sponsor Name:CHU DE BORDEAUX
    Full Title: Strategic treatment Pause of first-line Immune Check point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in good or intermediate risk with only one adverse prognostic factor in metastatic renal cell ...
    Medical condition: Metastatic renal cell carcinoma (mRCC) with a good or only one adverse prognostic factor intermediate risk per IMDC score
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000142-42 Sponsor Protocol Number: GR-2021-12373041 Start Date*: 2023-04-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis
    Medical condition: patients with secondary progressive MS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002003-33 Sponsor Protocol Number: EQ06.17.01 Start Date*: 2018-12-12
    Sponsor Name:FIDIA FARMACEUTICI S.P.A.
    Full Title: A double blind, double dummy, multicenter, randomized, placebo- and active-controlled clinical trial to evaluate effectiveness of Tricortin 1000 in patients affected by chronic low back pain
    Medical condition: Low Back Pain
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10052430 Chronic lumbago LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000973-26 Sponsor Protocol Number: SOGALDI-PEF Start Date*: 2022-06-01
    Sponsor Name:Faculdade de Medicina da Universidade do Porto
    Full Title: SOdium-Glucose cotransporter 2 inhibitor, ALDosterone AntagonIst, or both for heart failure with Preserved Ejection Fraction: a two-centre randomised three-treatment three-period crossover trial
    Medical condition: Heart Failure with Preserved Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002766-50 Sponsor Protocol Number: ProTrans-T1D Start Date*: 2017-10-12
    Sponsor Name:NextCell Pharma
    Full Title: A DOUBLE-BLINDED, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSE...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:18:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA